

Dear 5.1.2e

Mon 12/20/2021 7:45:39 PM

Received:

Thank you for your query. You will now have seen the press release and the summary of opinion. As stated in the press release, the original strain of SARS-CoV-2 and some variants of concern such as Alpha and Beta were the most common viral strains circulating when the studies were ongoing. There is currently limited data on the efficacy of Nuvaxovid against other variants of concern, including Omicron.

We will of course continue to follow up with the company to ensure that all data available is submitted for evaluation and provide updates when possible.

Best wishes

5.1.2e



